EY's latest Biotech Beyond Borders report acknowledges the seismic changes in the US in the last few months, including cuts ...

Fact checked by Vikki Velasquez More people need better medicines, and there is a rising demand for food and sustainable ...

A dramatic pullback in public biotech investment catalyzed by economic and regulatory upheaval is putting even more stress on ...

Biased AI models may lead to results that don’t accurately reflect populations. For example, if a dataset on which a model is ...

The U.S. AgTech sector is navigating a challenging investment climate. Macroeconomic headwinds, weak commodity prices and a ...

PwC analysts have warned the speedy evolution of the Chinese biotech sector is creating “heightened risks related to IP ...

In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.

China's biotechnology stocks have experienced a significant rally, outperforming AI, with a 60% surge since January due to ...

VANCOUVER, BC / ACCESS Newswire / June 19, 2025 / Right Season Investments Corp. (TSXV:LITT), ("Right Season" or the "Company") announces a strategic shift to increase its investment focus toward high ...

China’s biotechnology stocks have shaken off a four-year slump to be among the hottest performers in Asia this year and funds ...

China's biotechnology sector is experiencing notable growth, with the ChinaAMC Hang Seng Biotech ETF, tracking the Hang Seng ...